First Drug For Severe Alopecia Recommended By NICE Could Benefit 14,000 Patients

Ritlecitinib (Litfulo; Pfizer) has been recommended by the National Institute for Health and Care Excellence (NICE) as the first licensed treatment for severe alopecia areata in individuals aged 12 and over. This once-daily oral pill, a kinase inhibitor, has shown greater effectiveness than placebo in clinical trials, with hair regrowth improvements continuing for up to 2 years. NICE estimates that up to 14,000 people in England could benefit from this treatment. Initially not recommended, the decision was reversed after Pfizer provided additional information and a price discount. Alopecia areata is an autoimmune disease affecting hair follicles, and this recommendation marks a significant advancement for patients who previously lacked licensed treatment options through the NHS.